Biotech spin-out secures cancer funding

摘要

University of Cambridge biotechnology company PolyProx Thcrapuetics has raised ￡3.4 million in seed capital to finance development of its cancer treating drug technology.The Department of Pharmacology spin-out will develop a new class of drugs,based on Polyproxin molecules,that can selectively target and trigger natural degradation machinery within tumour cells.Christine Martin,Investment Manager at Cambridge Enterprise,said:”This is a great technology that is poised to address the elusive’difficult to drug’section of the protcomc to ultimately bring patient benefit.”